KESTRA MEDICAL TECHNOLOGIES, LTD. Fair Value Disclosure
8. Fair Value Measurement
The following table presents the Company’s fair value hierarchy for its classified assets and liabilities measured at fair value on a recurring basis as of April 30, 2026 and 2025.
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|||
April 30, 2026 |
|
|
|
|
|
|
|
|
|
|||
Assets |
|
|
|
|
|
|
|
|
|
|||
Money market funds |
|
$ |
22,146 |
|
|
$ |
— |
|
|
$ |
— |
|
U.S. treasury securities |
|
|
— |
|
|
|
195,338 |
|
|
|
— |
|
Total assets |
|
$ |
22,146 |
|
|
$ |
195,338 |
|
|
$ |
— |
|
Liabilities |
|
|
|
|
|
|
|
|
|
|||
Warrant liabilities |
|
|
— |
|
|
|
— |
|
|
|
1,369 |
|
Total liabilities |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,369 |
|
|
|
|
|
|
|
|
|
|
|
|||
April 30, 2025 |
|
|
|
|
|
|
|
|
|
|||
Liabilities |
|
|
|
|
|
|
|
|
|
|||
Warrant liabilities |
|
|
— |
|
|
|
— |
|
|
|
8,097 |
|
Total liabilities |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
8,097 |
|
The Company classifies its money market funds, which are valued based on quoted market prices in active markets with no valuation adjustment, as cash equivalents within the fair value hierarchy.
The fair value and amortized cost of available-for-sale marketable securities as of April 30, 2026 are presented in the following table:
|
|
|
|
|
Gross Unrealized |
|
|
|
|
|||||||
|
|
Amortized Cost Basis |
|
|
Unrealized Gains |
|
|
Unrealized Losses |
|
|
Fair Value |
|
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
22,146 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
22,146 |
|
U.S. treasury securities |
|
|
195,556 |
|
|
|
— |
|
|
|
(218 |
) |
|
|
195,338 |
|
Total |
|
$ |
217,702 |
|
|
$ |
— |
|
|
$ |
(218 |
) |
|
$ |
217,484 |
|
As of April 30, 2026 available-for-sale marketable securities are classified as follows in the consolidated balance sheet:
Category: |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
|
|
|
|
$ |
54,993 |
|
Short-term investments |
|
|
|
|
|
|
|
|
96,724 |
|
Long-term investments |
|
|
|
|
|
|
|
|
65,767 |
|
Total |
|
|
|
|
|
|
|
$ |
217,484 |
|
Short-term investments have a contractual maturity date that is one year or less from the respective balance sheet date. Long-term investments have a contractual maturity date that is more than one year from the respective balance sheet date. The Company recognized no credit losses during the years ended April 30, 2026 and 2025, and had no allowance for credit losses as of April 30, 2026, and 2025.
As of April 30, 2026 and 2025, the fair value of the long-term debt, net of discounts, approximated $47,700 and $47,330, respectively. The fair value of long-term debt was determined using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules and current market rates. Long-term debt has been classified as Level 2 of the fair value hierarchy.
There were no transfers into or out of the Level 1, 2 or 3 fair value hierarchies during the years ended April 30, 2026 and 2025.
Warrant Liabilities
As of April 30, 2026, the Company recorded warrant liabilities from issuance of warrants to the lender of the Term Loan 2024 in connection with the amendment on February 25, 2025. The warrant liabilities are based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The Company’s valuation of the warrant liabilities utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates to value the warrants.
As of April 30, 2026, the quantitative elements associated with the Company’s Level 3 inputs impacting the fair value measurement of the warrant liabilities included the fair value per share of the underlying Common Shares, the remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying Common Shares. The expected volatility is derived from comparable public companies as the Company did not have sufficient trading history for the Company’s Common Shares. The change in fair value of warrant liability was $2,673 for the year ended April 30, 2026, which is included in other expense within the consolidated statements of operations and comprehensive loss.
The following table presents the significant inputs and assumptions used in the Black-Scholes option pricing model to determine the fair value of the warrant liabilities as of April 30, 2026:
|
|
April 30, 2026 |
|
|
April 30, 2025 |
|
||
Strike price |
|
$ |
11.54 |
|
|
$ |
11.54 |
|
Expected term (in years) |
|
|
7.42 |
|
|
|
8.42 |
|
Expected volatility |
|
|
59.00 |
% |
|
|
65.00 |
% |
Risk free rate |
|
|
4.20 |
% |
|
|
4.21 |
% |
Dividend yield |
|
|
0 |
% |
|
|
0 |
% |
A reconciliation of the Level 3 liabilities is as follows:
Fair value of Level 3 liabilities as of April 30, 2025 |
|
$ |
8,097 |
|
Change in fair value of warrant liabilities |
|
|
(2,673 |
) |
Exercise of warrant |
|
|
(4,055 |
) |
Fair value of Level 3 liabilities as of April 30, 2026 |
|
$ |
1,369 |
|
Want the next KESTRA MEDICAL TECHNOLOGIES, LTD. fair value disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment KESTRA MEDICAL TECHNOLOGIES, LTD.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | Jul 14, 2026 | Showing above |
| 2025 | Jul 17, 2025 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.